Immutep Ltd Reveals Key LAG-3 Binding Discovery

Immutep Ltd (AU:IMM) has released an update.

Immutep Ltd, in collaboration with Monash University, has unveiled groundbreaking research in Science Immunology that illustrates how human LAG-3 binds to MHC Class II molecules. This discovery lays a crucial foundation for developing new LAG-3 blocking therapies, enhancing the potential of Immutep’s anti-LAG-3 small molecule program. Such advancements are pivotal for the company’s focus on cancer and autoimmune disease treatments, promising significant opportunities for investors.

For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.